Top Story

Graham-Cassidy proposal: What you need to know

September 21, 2017

The latest Republican legislation attempting to “repeal and replace” the Affordable Care Act drafted by Senators Lindsey Graham (R-S.C.) and Bill Cassidy, MD, (R-La.), and thus deemed the Graham-Cassidy proposal, has gained growing disapproval from several health care organizations, including the AMA and the American College of Physicians.

Within the past week, the AMA and the American College of Physicians (ACP) sent separate letters to the Senators conveying their strong opposition to the bill, citing as main concerns the loss of health care insurance for millions of Americans and its failure to “first, do no harm” to patients. The associations also urged the Senate to reject the legislation and reiterated recommendations to ensure affordable, quality coverage that is accessible to all patients across the country.

In the Journals

Poor clinical response in RA yields short-term risk for type 2 diabetes

September 21, 2017
Patients with rheumatoid arthritis who have a poor clinical response had a significant short-term risk for developing type 2 diabetes, according to results published in…
FDA News

FDA finalizes guidelines on interoperable devices

September 21, 2017
The FDA recently issued final guidelines outlining its nonbinding recommendations for safe and secure interactions among medical devices and other information systems…

Major physician groups urge Senate to stabilize health insurance markets

September 21, 2017
A coalition of major physician groups submitted a testimony to the Senate Health, Education, Labor and Pensions Committee emphasizing the importance of stabilizing…
In the Journals Plus

Rates of hip fracture, subsequent 1-year mortality differ by race

September 21, 2017
The incidence of hip fracture is highest among white men and lowest among Asian men, with Asian men also experiencing lower 1-year mortality risk than white, Hispanic…
More Headlines »

Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future

This activity is supported by educational funding provided by Amgen and Sanofi US and Regeneron Pharmaceuticals.

With each passing year we gain new insight and understanding around the clinical utilization of lipid-lowering…
More »
Meeting News

VIDEO: Heart failure most deadly complication of type 2 diabetes

July 16, 2017
More »
Resource Centers

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Current Issues
View the Current Issue